Form IRANNOTICE TAKEDA PHARMACEUTICAL
Tweet
Share
E-mailU.S. Securities and Exchange
Commission
100 F Street, N.E.
Washington, DC 20549
June 17, 2026
Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
Dear Sirs:
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Takeda Pharmaceutical Company Limited has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended March 31, 2026, which was filed with the Securities and Exchange Commission on June 17, 2026.
Sincerely,
| /s/ Milano Furuta | ||||||||||||||
| Milano Furuta | ||||||||||||||
Director and Chief Financial Officer | ||||||||||||||
Takeda Pharmaceutical Company Limited 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668, Japan | ||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Engineering Expert Chris Hanvey of Easley, SC, Breaks Down Inverter-Powered Grooming Vans for HelloNation
- ASUS Launches ExpertCenter Pro ET900N G3 Built on NVIDIA DGX Station Architecture
- Five Star Bancorp to open full-service branch in Lodi to serve Central Valley entrepreneurs and agribusinesses
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
